At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Folfox6 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Neoadjuvant Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating Folfox6, Gemcitabine, and 2 other interventions for Pancreas Neoplasm Malignant Resectable. Completed, enrolled 24 participants across 1 site.
Detailed Summary
To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreas Neoplasm Malignant Resectable
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedSep 2014
Primary CompletionJun 2017
Study CompletionJan 2020
TodayJul 2026
First PostedSep 17, 2014
Enrollment StartFeb 1, 2014
Primary CompletionJun 28, 2017
Study CompletionJan 14, 2020
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 11.8 years ago
Interventions
Folfox6drug
Gemcitabinedrug
Radiation Therapyradiation
Pancreaticoduodenectomy with retroperitoneal lymphadenectomyprocedure